Analyst Expectations for PDS Biotechnology's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 Wall Street analysts have provided ratings on PDS Biotechnology (NASDAQ:PDSB) with 3 bullish and 1 somewhat bullish, and no bearish ratings. The average price target is $20.75, which is significantly higher than the current price of $6.29. This target has decreased by 9.78% from the previous target of $23.00.
November 15, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a positive outlook on PDS Biotechnology with a high average price target of $20.75 compared to its current price of $6.29, despite a recent decrease in target price.
The unanimous bullish and somewhat bullish ratings from analysts suggest a strong positive sentiment towards PDSB. The significant difference between the current price and the target price indicates a potential for substantial short-term gains if market perception aligns with analyst expectations. However, the recent decrease in the target price may indicate some caution, hence the confidence is not at the maximum.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100